Madrigal Pharmaceuticals (MDGL) News Today

Madrigal Pharmaceuticals logo
$396.74 -1.34 (-0.34%)
Closing price 04:00 PM Eastern
Extended Trading
$396.50 -0.25 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is Madrigal Pharmaceuticals Down Today?

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) faces competing news: a partnership supporting its MASH program is a positive, but investor-law-firm investigations over allegations involving Rezdiffra are likely the more significant near-term concern.

  • Positive Sentiment: Madrigal agreed to a multi-year partnership with Sonic Incytes to advance non-invasive liver assessment in MASH. The collaboration could support disease assessment and the broader use of Madrigal’s MASH treatment, though the announcement did not disclose financial terms. Article: Sonic Incytes partnership
  • Neutral Sentiment: The company granted inducement equity awards to 23 newly hired non-executive employees. The routine hiring-related awards are unlikely to be a major stock catalyst. Article: Inducement awards
  • Negative Sentiment: Several law firms announced investigations into potential securities-law violations. Hagens Berman says its inquiry concerns whistleblower allegations about the integrity of Rezdiffra clinical safety data and regulatory compliance, and whether the company or senior management misrepresented or concealed material information. These are allegations under investigation, not established findings, but the scrutiny may increase legal, regulatory and reputational uncertainty for MDGL. Article: Hagens Berman investigation notice Article: Kaplan Fox investigation alert
Posted 2h agoAI Generated. May Contain Errors.

Madrigal Pharmaceuticals Latest News

What is HC Wainwright's Estimate for MDGL Q1 Earnings?
Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals Media Mentions By Week

Madrigal Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MDGL
News Sentiment
▼
0.19

0.39
▲
Average
Healthcare
News Sentiment

Madrigal Pharmaceuticals News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MDGL Articles
This Week
▼
13

6
▲
MDGL Articles
Average Week

Madrigal Pharmaceuticals Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
7
+133%
Page Views
1,946
+3%
Get Madrigal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Madrigal Pharmaceuticals dated 11/19/2026.
From Our Partners